LifeMD (NASDAQ:LFMD) Given New $14.00 Price Target at BTIG Research

LifeMD (NASDAQ:LFMD) had its target price hoisted by equities research analysts at BTIG Research from $13.00 to $14.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 40.00% from the company’s current price.

Separately, HC Wainwright lifted their price objective on LifeMD from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, January 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $10.40.

LifeMD Trading Up 3.1 %

NASDAQ LFMD opened at $10.00 on Tuesday. LifeMD has a 12 month low of $1.40 and a 12 month high of $12.01. The stock’s fifty day moving average price is $9.06 and its 200-day moving average price is $7.64. The stock has a market cap of $403.70 million, a P/E ratio of -14.29 and a beta of 1.43. The company has a current ratio of 1.22, a quick ratio of 1.15 and a debt-to-equity ratio of 3.22.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. The firm had revenue of $44.86 million for the quarter, compared to the consensus estimate of $40.65 million. As a group, equities analysts forecast that LifeMD will post -0.14 EPS for the current fiscal year.

Institutional Trading of LifeMD

Large investors have recently modified their holdings of the company. G2 Investment Partners Management LLC lifted its stake in shares of LifeMD by 23.9% in the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock worth $5,704,000 after purchasing an additional 132,850 shares during the period. Cantor Fitzgerald L. P. purchased a new stake in LifeMD during the fourth quarter valued at approximately $653,000. Tower Research Capital LLC TRC boosted its stake in shares of LifeMD by 266.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $38,000 after acquiring an additional 3,348 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of LifeMD during the 4th quarter worth $815,000. Finally, Jump Financial LLC grew its position in shares of LifeMD by 50.2% during the 4th quarter. Jump Financial LLC now owns 111,738 shares of the company’s stock valued at $926,000 after acquiring an additional 37,339 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.